Fast-Acting Small Molecules Targeting Malarial Aspartyl Proteases, Plasmepsins, Inhibit Malaria Infection at Multiple...

Area of Science:

• Medicinal Chemistry
• Parasitology
• Drug Discovery

Background:

• Malaria eradication is hindered by complex Plasmodium parasite life cycles and emerging drug resistance.
• There is an urgent need for new, affordable antimalarials effective against multiple parasite stages.

Purpose of the Study:

• To synthesize and evaluate novel hydroxyethylamine compounds for antimalarial activity.
• To investigate the compounds' efficacy against various Plasmodium parasite life stages and drug-resistant strains.

Main Methods:

• Synthesis of novel hydroxyethylamine compounds.
• In vitro testing against Plasmodium falciparum blood stages and plasmepsins.
• In vivo testing in Plasmodium berghei infected mouse models.
• Evaluation of activity against gametocyte and liver stages.

Main Results:

• All tested compounds inhibited P. falciparum blood stages at submicromolar concentrations.
• The most effective compounds showed IC50 values around 500 nM against drug-resistant P. falciparum.
• Compounds demonstrated inhibitory action against malarial plasmepsins.
• Significant reduction in blood parasite load observed in mouse models.
• Two compounds inhibited P. falciparum gametocytes and P. berghei liver stages in vitro and in vivo.

Conclusions:

• Novel hydroxyethylamine-phthalimide analogs are effective against multiple Plasmodium parasite life stages.
• These compounds show potential as a valuable chemical lead for developing new antimalarial drugs.
• The fast-acting nature and multi-stage targeting offer a promising strategy against malaria.